Curato implements Sectra MicroDose Mammography at three clinics

“As a private care provider, being competitive and efficient is particularly important”

The Norwegian company Curato, one of the Nordic region's largest companies in the area of radiology examinations, has now fully implemented Sectra's (STO:SECTB) digital mammography system, Sectra MicroDose Mammography, at three of their mammography clinics.

"As a private care provider, being competitive and efficient is particularly important," says Hans Olav Almaas, President of Curato. "We now conduct examinations with a significantly lower radiation dose than other players in the private market can offer. We have already examined more than 2,500 women using our new system, and many have expressed their appreciation."

Curato has made major investments in the modernization of its mammography operations. The decision to invest in Sectra MicroDose Mammography was made in November 2009, and the company now has a complete future-proof comprehensive solution for efficient digital mammography screening. Sectra MicroDose offers improved or identical image quality at a significantly lower radiation dose than all other solutions in the market. The comprehensive solution that Curato has selected also contributes to a more efficient workflow, in which images and patient information are available wherever they are required, regardless of time and place.

Source:

Sectra Group

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered MRI predicts outcomes in prostate cancer